Company Overview
Unike is based on the forefront of global biomedicine, with disruptive original technology as its core, gathering top scientific research and industry elites from around the world, and deeply cultivating the high-quality track of long-acting protein peptide innovative drugs. Targeting the core pain points of the industry's difficulty in developing and breaking through traditional Chinese medicine, relying on the exclusive original ZT technology platform, we focus on the research and development of innovative drugs for major diseases. Committed to creating a global hub for innovative research and development of long-acting peptides, filling unmet clinical needs, and safeguarding human life and health.
Corporate Culture
Vision: To become the birthplace of global long-acting protein peptide innovative drugs
Mission: Focus on technological revolution, continue to specialize in researching good drugs, and safeguard human life and health
Values: Innovation, Focus, Efficiency, Rigorousness, Win Win
The company always adheres to the core concept of innovation first and technology oriented, overcomes pharmaceutical research and development problems with cutting-edge technology, polishes the quality of innovative drugs with rigorous craftsmanship, links global industrial resources with openness and win-win, and continues to create long-term value for the upgrading of the biopharmaceutical industry and global patient health
Core Advantages
Autonomous platform technology：
The ZT technology platform independently developed by the company has been published in several top international academic journals and selected as one of the top ten milestone technologies in Nature. We have obtained patent authorizations from multiple countries including China, the United States, Europe, and Japan, and have established a strong global patent barrier. Based on the excellent physical and chemical properties and unique molecular structure of ZT technology platform, efficient, low-cost, and scalable protein peptide drug research and development can be achieved. At present, 26 first-class innovative drugs have been developed, covering major disease fields such as metabolism, oncology, and immunology, with broad prospects for industrialization.
Enrich product pipeline：
Based on the ZT original technology platform, expand the indications layout in multiple dimensions, build a gradient innovative drug product pipeline, and form a multi-level project matrix of "early research and development+preclinical candidate molecules".
Professional R&D team：
The core R&D team of the company is mostly composed of students and colleagues trained by Dr. Zou Peijian at the Chinese Academy of Sciences. They have 15 years of R&D experience in the field of peptide protein drugs and have profound research on various long-acting technologies, competitors, and industry trends in the industry. They have undertaken multiple national projects and completed the research and development of more than 10 long-acting protein drugs, which have been recognized by partners; The other part of the core team comes from large pharmaceutical companies and Fortune 500 companies, with profound experience in drug lifecycle management. They are familiar with the standardized operation system of the enterprise and skilled in building efficient R&D collaboration platforms and compliance management frameworks, ensuring that the entire process of innovative projects from concept to implementation is controllable. They have built a compliance system covering the entire chain of R&D, production, and distribution, providing guidance for start-up teams on the entire process from clinical trial design to drug marketing authorization. Especially in the field of technical cooperation, the abundant pharmaceutical industry resources accumulated in the early stage can quickly convert research results into orders, accelerating the company's development and growth.